Syndax Pharmaceuticals (SNDX) Retained Earnings (2015 - 2026)

Syndax Pharmaceuticals' Retained Earnings history runs 12 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 18.63% year-over-year to -$1.5 billion; the TTM figure through Mar 2026 stood at -$1.5 billion (down 18.63% YoY), while the FY2025 annual figure was -$1.5 billion, down 23.37% from the prior year.
• Retained Earnings was -$1.5 billion for Q1 2026 at Syndax Pharmaceuticals, down from -$1.5 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$580.9 million in Q1 2022 to a low of -$1.5 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$1.0 billion across 5 years, with a median of -$974.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings grew 2.6% in 2022, then tumbled 35.79% in 2024.
• A 5-year view of Retained Earnings shows it stood at -$693.0 million in 2022, then plunged by 30.21% to -$902.4 million in 2023, then slumped by 35.32% to -$1.2 billion in 2024, then fell by 23.37% to -$1.5 billion in 2025, then retreated by 2.83% to -$1.5 billion in 2026.
• The last three Retained Earnings figures came in at -$1.5 billion (Q1 2026), -$1.5 billion (Q4 2025), and -$1.4 billion (Q3 2025), per Business Quant data.